Longer Gap Between Doses Boosts Durability of Self-Amplifying mRNA H5N1 Flu Vaccine in Phase 1 Trial

Avian influenza has long hovered at the edge of pandemic planning. H5N1 viruses circulate widely in wild birds and poultry, have repeatedly spilled over into mammals, and continue to cause sporadic severe infections in people exposed to infected animals. Should an H5N1 strain acquire efficient human-to-human transmission, the world would need vaccines that can be produced quickly, deployed at scale, and—crucially—that generate immune responses robust enough to protect a population with no pre-existing immunity. A new Phase 1 clinical trial, published in Nature Communications, reports encouraging progress on all three fronts for a next-generation vaccine platform known as self-amplifying mRNA.

The study, conducted by investigators at CTI Clinical Trial and Consulting Services together with a research team at Arcturus Therapeutics, evaluated ARCT-2304, a bicistronic self-amplifying mRNA vaccine encoding both the hemagglutinin (HA) and neuraminidase (NA) surface proteins of H5N1 influenza. Unlike conventional messenger RNA vaccines, which deliver synthetic mRNA that is translated a limited number of times before it is degraded, self-amplifying mRNA carries additional genetic instructions derived from an alphavirus replicase machinery. Once inside host cells, the construct directs the production of an RNA-dependent RNA polymerase complex that copies the vaccine’s own mRNA, dramatically amplifying the amount of antigen produced per delivered molecule. This intrinsic amplification is the basis of the technology’s most touted advantage: dose sparing, the ability to achieve strong immune responses with far smaller antigen quantities than conventional mRNA or protein-based vaccines require.

Encoding both HA and NA is also strategically significant. Hemagglutinin is the principal target of neutralizing antibodies and the focus of most influenza vaccine design, because antibodies that bind HA can block the virus from entering cells. Neuraminidase, by contrast, facilitates the release of newly formed viral particles from infected cells, and antibodies against NA can reduce viral shedding, limit transmission, and temper disease severity. Traditional inactivated influenza vaccines elicit strong anti-HA responses but comparatively weak anti-NA immunity. By co-delivering both antigens on a single self-amplifying mRNA backbone, ARCT-2304 was designed to stimulate two complementary arms of antiviral humoral defense simultaneously—an approach that could prove valuable if a pandemic virus proves less uniformly susceptible to HA-focused immunity.

The trial itself was a randomized, observer-blind, dose-finding Phase 1 study registered as NCT06602531, enrolling 212 healthy adults. Participants received two doses of ARCT-2304 at one of three dose levels—1.5, 5, or 12 micrograms—or a control/placebo preparation, with the two vaccinations spaced either four or eight weeks apart. Observer blinding means the clinicians who assessed participants after vaccination did not know which product each volunteer had received, reducing bias in the evaluation of solicited and unsolicited adverse events. The primary outcomes were safety and reactogenicity, along with immunogenicity measured twenty-eight days after the second dose using hemagglutination inhibition (HAI) assays for HA-directed antibodies and enzyme-linked lectin assays for NA-directed antibodies. Importantly, the researchers benchmarked their immunogenicity results against serum samples from a prior clinical study that had supported the licensure of an existing H5N1 vaccine, providing a regulatory-grade yardstick rather than an arbitrary threshold.

On safety, the news was straightforward: ARCT-2304 was well tolerated across all dose levels and both dosing schedules. Solicited adverse events—symptoms participants were actively asked about, such as injection-site pain, fatigue, headache, and fever—were mostly mild to moderate in severity and transient, resolving without lasting effects. The frequency and intensity of these reactions were dose-dependent, a familiar pattern for mRNA-based vaccines in which higher antigen doses tend to provoke somewhat stronger local and systemic reactions. No safety concerns were identified during the trial, and no pattern emerged that would suggest the self-amplifying vector behaves differently in this respect from conventional mRNA platforms, a point of interest given that alphavirus-derived replicase sequences have occasionally raised questions about innate immune stimulation and tolerability.

The immunogenicity data carried the study’s central message. Two doses of ARCT-2304 elicited robust humoral responses against both the HA and NA antigens, with antibody titers rising across all evaluated dose levels. But the most consequential finding concerned timing: participants whose two doses were spaced eight weeks apart developed antibody responses that were both higher in magnitude and more durable than those of participants vaccinated on the four-week schedule. Neutralizing antibodies and anti-NA antibodies in the extended-interval groups remained significantly elevated six to seven months after the second dose. This echoes a pattern observed across vaccinology and, notably, in the COVID-19 pandemic, where longer intervals between prime and boost consistently produced stronger and longer-lived antibody responses—likely because the interval gives germinal center reactions time to mature, allowing B cells to undergo additional rounds of affinity maturation before the booster dose re-stimulates them.

For pandemic preparedness, that durability finding is double-edged in an interesting way. A longer dosing interval requires more calendar time to fully immunize a population, which is a liability in the earliest, fastest-moving phase of an outbreak. But pandemic vaccine campaigns typically unfold over many months, and stockpiled or rapidly manufactured doses may need to protect recipients for half a year or more before a well-matched pandemic strain even arrives or before waves subside. An eight-week schedule that yields antibodies still substantially elevated at six to seven months offers a more favorable durability profile than a compressed schedule whose protection wanes sooner. The results suggest that pandemic vaccination strategies could deliberately trade a slightly longer immunization window for substantially longer-lasting immunity.

Beyond antibodies, the trial examined cellular immunity, an increasingly recognized determinant of vaccine protection against respiratory viruses. ARCT-2304 induced T-cell responses that were dose-dependent and skewed toward a Th1-polarized profile, peaking around day 29 of the study. Th1 polarization matters because it reflects a helper T-cell orientation toward antiviral effector functions—supporting CD8 T-cell activity and antibody class switching—rather than the Th2-skewed responses that have historically been a concern in some vaccine contexts. T-cell help is also central to the germinal center processes that underpin the antibody durability advantage seen with extended dosing intervals, making the cellular and humoral findings mutually reinforcing rather than independent observations.

The trial was funded with federal funds from the U.S. Department of Health and Human Services through the Administration for Strategic Preparedness and Response and the Biomedical Advanced Research and Development Authority (BARDA) under contract number 75A50122C00007. According to the paper, the funder reviewed the study design and clinical trial data and approved the decision to submit the manuscript, but had no role in data analysis or manuscript writing. Most of the scientific authors are employees of Arcturus Therapeutics, the vaccine’s manufacturer, and hold company stock options; the lead clinical investigator received fees for study participation. These relationships are disclosed in the publication and are worth noting when weighing the results, though the benchmarked immunogenicity approach and independent regulatory precedent for the comparison sera lend methodological credibility to the findings.

Taken together, the study supports advancing self-amplifying mRNA platforms as a serious component of pandemic influenza preparedness, and it does so with a lesson about immunization schedule design that could shape future pandemic playbooks. Several questions remain open. Phase 1 trials in healthy adults cannot establish efficacy against actual H5N1 infection, and larger studies will be needed to confirm the durability signal over longer horizons, test the vaccine against drifting viral clades, and evaluate populations such as older adults who respond less vigorously to influenza vaccines. The dose-sparing potential of the platform also invites further dose-ranging work, since a lower effective dose translates directly into more doses manufactured per batch—a decisive variable in a genuine pandemic. Still, the demonstration that a bicistronic self-amplifying mRNA vaccine can elicit strong, durable, dual-antigen immunity against H5N1 with an acceptable safety profile marks a meaningful step from laboratory promise toward strategic readiness. If H5N1’s ongoing expansion in animals eventually forces the question of pandemic vaccination, the answer may well involve letting a little more time pass between doses.

Subject of Research: A Phase 1 trial of a self-amplifying mRNA vaccine targeting H5N1 influenza

Article Title: Extended dosing intervals enhance the durability of a self-amplifying mRNA vaccine against pandemic H5N1 influenza: a randomized, observer-blind, dose-finding Phase I study

Article References: Pragalos, A. A., Pacciarini, F., Jin, H., Hopkins, T., Zhang, Y., Bugarini, R., Liu, X., Sullivan, B. M., Verhoeven, C., & Smolenov, I. (2026). Extended dosing intervals enhance the durability of a self-amplifying mRNA vaccine against pandemic H5N1 influenza: a randomized, observer-blind, dose-finding Phase I study. Nature Communications. https://doi.org/10.1038/s41467-026-78031-9

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78031-9

Keywords: H5N1 influenza, self-amplifying mRNA, ARCT-2304, Phase 1 trial, pandemic preparedness, hemagglutinin, neuraminidase, dose interval, antibody durability, BARDA, vaccine immunogenicity, Arcturus Therapeutics